Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

NEM® + BIOCURC® Versus Placebo in Exercised-induced Joint Pain, Stiffness, & Cartilage Turnover in Healthy Men & Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03769857
Recruitment Status : Completed
First Posted : December 10, 2018
Last Update Posted : July 18, 2019
Sponsor:
Collaborator:
QPS Bio-Kinetic
Information provided by (Responsible Party):
ESM Technologies, LLC

Brief Summary:
This study is intended to evaluate the combined effects of the dietary supplement NEM® brand eggshell membrane and BIOCURC® brand bioavailable curcumin versus placebo in reducing exercise-induced joint pain, stiffness & cartilage turnover in healthy men & women. Half of the study participants will receive NEM+BIOCURC, once daily, orally while the other half of the study participants will receive placebo, once daily, orally while performing an exercise regimen every other day for two weeks.

Condition or disease Intervention/treatment Phase
Exercise-induced Joint Pain Exercise-induced Joint Stiffness Exercise-induced Joint Cartilage Turnover Dietary Supplement: NEM® + BIOCURC® Dietary Supplement: Placebo Not Applicable

Detailed Description:
Moderate exercise can induce discomfort in joints when done infrequently or when done too intensely or for too long a period. This discomfort is often realized as either pain or stiffness in the joint that was the focus of the exercise. For example, one's knees will hurt after jogging for several miles, particularly if jogging for the first time. This study is intended to evaluate whether the combination of NEM® brand eggshell membrane and BIOCURC® brand bioavailable curcumin can alleviate joint pain or stiffness, either directly following exercise or 12 hours post-exercise versus placebo. The study will also evaluate the combination's effect, on cartilage turnover via the cartilage degradation biomarker c-terminal cross-linked telopeptide of type II collagen (CTX-II). Participants will perform a minimum of 50 steps per leg utilizing an aerobics step at the clinical site. They will follow this exercise regimen on alternating days for 2 consecutive weeks. Changes in pain & stiffness (immediate & 12-hour) will be compared to both baseline and to the placebo group. Urine samples will also be collected at baseline and at the end of Week 1 & Week 2. The change in CTX-II from baseline will be compared to the placebo group.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: treatment versus placebo
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Quadruple Blind
Primary Purpose: Supportive Care
Official Title: Efficacy of NEM® Brand Eggshell Membrane Plus BIOCURC® Brand Bioavailable Curcumin Versus Placebo in Exercised-induced Joint Pain, Stiffness, & Cartilage Turnover in Healthy Men & Women
Actual Study Start Date : January 13, 2019
Actual Primary Completion Date : February 20, 2019
Actual Study Completion Date : April 15, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NEM® + BIOCURC®

NEM® + BIOCURC®

NEM, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS BIOCURC, 350 mg, #10 oval softgel, once daily orally for 2 weeks

Dietary Supplement: NEM® + BIOCURC®
Dietary supplement combination for the support of joint health.

Placebo Comparator: Placebo
Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS Placebo, 350 mg, #10 oval softgel, once daily orally for 2 weeks
Dietary Supplement: Placebo
Placebo




Primary Outcome Measures :
  1. Exercise-induced Cartilage Turnover via CTX-II Biomarker [ Time Frame: 2 Weeks ]
    To evaluate the efficacy of NEM®+BIOCURC® versus placebo at reducing exercise-induced cartilage turnover in healthy men & women by evaluating the change in urinary CTX-II levels.


Secondary Outcome Measures :
  1. Exercise-induced Joint Pain via questionnaire [ Time Frame: 2 Weeks ]
    To evaluate the efficacy of NEM®+BIOCURC® versus placebo at reducing exercise-induced knee discomfort (pain/aching) based upon perceived pain rated on a 0-10 point continuous scale (where 0 = no pain).

  2. Exercise-induced Joint Stiffness via questionnaire [ Time Frame: 2 Weeks ]
    To evaluate the efficacy of NEM®+BIOCURC® versus placebo at reducing exercise-induced knee stiffness based upon perceived stiffness rated on a 0-10 point continuous scale (where 0 = no stiffness).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or Female subjects must be 40-75 years of age at the time of Screening.
  2. Subjects must not have been diagnosed with a JCT disease (i.e. osteoarthritis, rheumatoid arthritis, spondyloarthritis, bursitis, gout, systemic lupus erythematosus, fibromyalgia, etc.) affecting the hip, knee, or ankle by a licensed physician prior to enrollment evaluation / screening.
  3. Subjects must have a resting pain/discomfort score of ≤ 2 on the 10-point continuous scale in the knee with the most severe pain/discomfort at the Follow-Up Screening/Baseline (first exercise visit).
  4. Subjects must be willing and healthy enough, as judged by the clinical Investigator or Sub-Investigator(s), to perform moderate exercise.
  5. Subjects must be available for and willing to attend all evaluation visits.
  6. Subjects must be able and willing to give informed consent.
  7. Subjects must be willing to use only acetaminophen as rescue pain medication, if needed.
  8. Subjects participating in prior studies evaluating eggshell membrane, curcumin, fish oil or collagen can participate in the present study so long as they are not currently taking an eggshell membrane, fish oil, curcumin, or collagen supplement and have not done so for 60 days prior to screening.

Exclusion Criteria:

  1. Subject is currently receiving therapy with remission-inducing drugs (i.e. methotrexate, TNF biologics, etc.), immunosuppressive drugs (i.e. corticosteroids, transplantation medications, etc.) or planning to use these products during the study period.
  2. Subject has been diagnosed with any clinically significant confounding inflammatory disease or condition that would interfere with the study evaluation, as judged by the clinical investigator (i.e. pseudo gout, Paget's disease, chronic pain syndrome, active rheumatic fever, etc.).
  3. Subject has known allergy to any of the investigational products, including but not limited to eggs or egg products and rice or rice flour. If any subject becomes sensitive during the study, they will immediately be excluded from continuing in the study.
  4. Subject suffers from clinically significant cardiac, pulmonary, or other complications that would prevent them from performing moderate exercise or could pose a risk to the subject's health, as judged by the clinical investigator.
  5. Subject participates in activities involving intensive use of the lower extremities (i.e. running / jogging, sports, bicycling, dancing, etc.) 2 or more days per week or participates in activities that involve moderate use of the lower extremities (i.e. walking, golfing, yoga, etc.) 3 or more days per week.
  6. Subject's body weight is greater than 300 pounds (136.1 kg) at the time of Screening.
  7. Subject is currently taking or is unwilling to forgo the use of prescription, over-the-counter (OTC) treatments, and/or dietary supplements affecting joint health within 30 days prior to baseline evaluation and for the duration of the study. Prohibited medications include: NSAIDs, analgesics (other than acetaminophen), opioids, anti-depressants (of all drug classes for this indication, including but not limited to SSRI's such as citalopram and fluoxetine, TCA's such as amitriptyline and amoxapine, SNRI's such as duloxetine or SNRI's used for fibromyalgia such as milnacipran and NDRI's such as bupropion), other medications for the management of painful conditions (i.e. fibromyalgia) including gabapentin and tizanidine & joint supplements. Examples of these types of medications are: aspirin, ibuprofen, naproxen, oxycodone, propoxyphene, diclofenac, celecoxib, amitriptyline, duloxetine, glucosamine, chondroitin, MSM, white willow bark, turmeric or curcumin, Boswellia, fish oil, etc.

    a. Washout Periods: Subjects are eligible to participate in the study following a 7-day washout period for opioids, a 14-day washout period for analgesics & NSAIDs, and a 90-day washout period for steroids, anti-depressants, or JCT dietary supplements (i.e. glucosamine, chondroitin, MSM, etc.) Acetaminophen must not have been taken within 24 hours of the first baseline evaluation.

  8. Subject is involved in any other research study involving an investigational product (drug, device or biologic) or a new application of an approved product, within 30 days of the first baseline evaluation.
  9. Pregnant and breastfeeding women, or women who intend to become pregnant during the course of the study.
  10. Subject has a history or positive test result of HIV, hepatitis B or hepatitis C.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03769857


Locations
Layout table for location information
United States, Missouri
QPS Bio-Kinetic
Springfield, Missouri, United States, 65802
Sponsors and Collaborators
ESM Technologies, LLC
QPS Bio-Kinetic
Investigators
Layout table for investigator information
Study Chair: Kevin Ruff, Ph.D. ESM Technologies, LLC

Layout table for additonal information
Responsible Party: ESM Technologies, LLC
ClinicalTrials.gov Identifier: NCT03769857     History of Changes
Other Study ID Numbers: ESM-CLN#2019T01
First Posted: December 10, 2018    Key Record Dates
Last Update Posted: July 18, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by ESM Technologies, LLC:
exercise-induced
joint pain
joint stiffness
cartilage turnover
CTX-II

Additional relevant MeSH terms:
Layout table for MeSH terms
Arthralgia
Joint Diseases
Musculoskeletal Diseases
Pain
Neurologic Manifestations
Signs and Symptoms